Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 13, 2023

SELL
$5.57 - $11.01 $65,893 - $130,248
-11,830 Reduced 13.37%
76,657 $481,000
Q3 2022

Nov 14, 2022

BUY
$5.34 - $12.79 $95,473 - $228,672
17,879 Added 25.32%
88,487 $934,000
Q1 2022

May 16, 2022

BUY
$8.42 - $15.32 $49,004 - $89,162
5,820 Added 8.98%
70,608 $648,000
Q4 2021

Feb 11, 2022

BUY
$14.59 - $23.26 $945,256 - $1.51 Million
64,788 New
64,788 $978,000

Others Institutions Holding CRBU

About Caribou Biosciences, Inc.


  • Ticker CRBU
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 60,840,800
  • Market Cap $123M
  • Description
  • Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1...
More about CRBU
Track This Portfolio

Track Ensign Peak Advisors, Inc Portfolio

Follow Ensign Peak Advisors, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ensign Peak Advisors, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ensign Peak Advisors, Inc with notifications on news.